Navigation Links
Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Greece by SpePharm
Date:6/29/2009

Two MuGard US Patents Issued

DALLAS, June 29 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), announced today that its European partner, SpePharm has commenced commercial launch of MuGard in Greece. This follows previous commercial launches in Germany, Italy and the UK. Under a license from Access Pharmaceuticals, SpePharm is responsible for manufacturing, regulatory approval and commercialization in the 27 countries of Europe. SpePharm plans to launch MuGard in the rest of Europe over the coming 12 to 18 months. The license agreement includes royalties on net sales to Access.

Additionally, the Company announced that two MuGard(TM) patents have been issued from the United States Patent and Trademark Office, as US Patent numbers 7,544,348 and 7,547,433. The second patent includes claims on formulations with actives against mucocutaneous disorders, which provides protection of product line extensions.

MuGard is a novel, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 40% of all patients receiving chemotherapy and/or radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.

MuGard forms a protective coating over the oral mucosa when swirled gently around the mouth. In a comparison of cancer patients receiving standard mucositis care with those patients receiving MuGard, the incidence and severity of mucositis was significantly lower in the MuGard treated group using a validated scale for the assessment of oral mucositis.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for ProLindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and initiate clinical trials, the value of its products in the market (including MuGard and the size of the overall market for mucositis products), its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.


'/>"/>
SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Baxa Corporations Dennis Tribble, PharmD, Now Profiled at Expert411.com for Media and Professional Access
2. Americans' Right to Access Natural Health Alternatives in Peril, Says Natural Health Freedom Movement
3. Regence Members in Oregon Can Now Access Provider Cost Information
4. Neuropathy Patients, Doctors and Medical Professionals Rally in Sacramento to Demand Access to Lifesaving Medical Treatments
5. Eukanuba Unleashes New Free iPhone Application Providing Dog Owners With Instant Access to Dog Parks and Other Four-Legged Fun
6. Iran Blocks Access to the Chopra Center's Web Site, Podcasts, and Blogs
7. BRIT1 allows DNA repair teams access to damaged sites
8. AMA Supports Health System Reform Alternatives Consistent With Principles of Pluralism, Freedom of Choice, Freedom of Practice and Universal Access for Patients
9. Access Pharmaceuticals Announces Initiation of Two New Cobalamin(TM) Oral Insulin Drug Delivery Collaborations
10. Proposed Senate Health Care Cuts Will Reduce Health Care Access for All Michigan Citizens
11. GlaxoSmithKline 13th Annual IMPACT Awards Seek Nonprofits Providing Access to Healthcare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... For the sixth consecutive year, ... Technology (ICT) companies in the annual Branham300 listing. For 23 years, the Branhan300 ... ranked by revenue. , “We are honored to be on the Branham300 ...
(Date:5/3/2016)... City, NJ (PRWEB) , ... May 03, 2016 ... ... announced the general availability of the latest release of DocAve 6 Service ... release, AvePoint helps organizations migrate to SharePoint 2016 and take advantage of the ...
(Date:5/3/2016)... ... May 03, 2016 , ... Hydra Skin Sciences, a top-rated ... Allegro Anti-aging Cream, a revolutionary new anti-aging skin care product that integrates ... damaged skin, has sold over seventy-five thousand units worldwide within the first two months ...
(Date:5/3/2016)... (PRWEB) , ... May 03, ... ... Carnival Cruise Lines premiered the state-of-the-art Carnival Vista – the line’s largest ... ship, The Cruise Web has created an infographic spotlighting the Carnival ...
(Date:5/2/2016)... ... 02, 2016 , ... Those who may be considering seeking ... useful information in a new video released by Serenity Recovery, a holistic treatment ... viewed on the Serenity Recovery YouTube channel, examines various treatment methods and strategies, ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... BROOMALL, Pa. , May 3, 2016 ... Attorney Jack Whelan and Delaware County ... NARCAN® (naloxone HCI) Nasal Spray in all ACME ... the U.S. Centers for Disease Control and Prevention (CDC), naloxone has ... 2014, when police officers in Delaware County ...
(Date:5/3/2016)... Pharmaceutical giant Johnson & Johnson has been ... says its talc-based powder products caused ovarian cancer. The ... million in compensatory damages and $50 million in punitive ... , This is the second in a ... same court awarded $72 million to the family of ...
(Date:5/3/2016)... Global and Chinese Surgical ... overview of the industry that covers definition, applications ... report explores into the international and Chinese players ... Surgical Mesh market spread across 150 pages providing ... is available at http://www.reportsnreports.com/reports/470569-global-and-chinese-surgical-mesh-industry-2016-market-research-report.html . ...
Breaking Medicine Technology: